Urica Therapeutics

Urica Therapeutics, Inc. ("Urica") is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for gout and other diseases associated with hyperuricemia. Urica has obtained the rights to develop and commercialize dotinurad in the United States, the United Kingdom, the European Union, Canada, the Middle East and North Africa (MENA) region, and Turkey from Fuji Yakuhin Co. Dotinurad is a potential best-in-class URAT1 inhibitor that has received approval in Japan for the treatment of gout and hyperuricemia and is currently undergoing Phase I clinical trials in the United States. Urica was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).